Novartis may have abandoned one Sjögren's syndrome asset this year, but it looks like the drugmaker has a winner on its hands ...

A new tool from the lab of Velia Therapeutics co-founder Alan Saghatelian, Ph.D., has proven capable of scouring genetic data for tiny proteins that may serve as new therapeutic targets, opening the ...